Pfizer Inc. $PFE Holdings Increased by Willis Investment Counsel

Key Points

• Willis Investment Counsel increased its Pfizer stake by 5.9% during the second quarter, bringing its holdings to 1.82 million shares valued at approximately $43.8 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77, beating estimates of $0.68, while revenue reached $15.03 billion versus the $14.40 billion consensus. The company reaffirmed fiscal 2026 EPS guidance of $2.80–$3.00.
• Pfizer declared a quarterly dividend of $0.43 per share, equivalent to an annualized yield of about 6.4%. Analysts maintain a consensus “Hold” rating with an average price target of $28.28.

Willis Investment Counsel boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,818,508 shares of the biopharmaceutical company's stock after acquiring an additional 100,571 shares during the quarter. Pfizer comprises about 2.1% of Willis Investment Counsel's investment portfolio, making the stock its 9th biggest position. Willis Investment Counsel's holdings in Pfizer were worth $43,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Keb Asset Management LLC purchased a new stake in Pfizer in the 2nd quarter worth about $26,000. HFM Investment Advisors LLC lifted its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Evolution Wealth Management Inc. lifted its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Finally, Abound Financial LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.3%

Shares of NYSE PFE opened at $26.88 on Tuesday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The firm has a market cap of $153.21 billion, a PE ratio of 35.37 and a beta of 0.34. The business has a fifty day simple moving average of $25.15 and a two-hundred day simple moving average of $26.20. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer's payout ratio is 226.32%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PFE shares. HSBC cut Pfizer from a "buy" rating to a "hold" rating and cut their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. BMO Capital Markets cut their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, July 13th. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 29th. Wolfe Research reissued an "underperform" rating and set a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $28.28.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source